UK Competition Body Backs Up Claim That Pfizer & Flynn Abused Dominant Position With ‘Excessive’ Prices
Executive Summary
The UK CMA has explained why it believes Pfizer and Flynn Pharma abused a dominant market position by charging “excessive and unfair” prices for a generic epilepsy drug, while the two companies have laid out their the grounds for appealing against the decision.
You may also be interested in...
Court Ruling On Pfizer Price Hikes Could Delay Other Investigations, Warns UK Competition Authority
Ongoing Investigations into drug price increases could be at risk following a tribunal ruling in the UK phenytoin sodium case, according to the Competition and Markets Authority, which is considering an appeal against the judgment.
UK Fine For Pfizer/Flynn’s ‘Excessive And Unfair’ Pricing Sends Clear Message To Others
The UK competition authority has fined Pfizer and Flynn Pharma a total of £90m for charging “excessive and unfair” prices for phenytoin sodium capsules; Pfizer has said it will appeal. With an earlier CMA decision to impose a hefty fine on GlaxoSmithKline for its part in a pay-for-delay deal, companies should pay careful consideration to any competition issues raised by their pricing strategies for marketed drugs.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.